Dr. Martens plc (LON:DOCS - Get Free Report) insider Ije Nwokori bought 189 shares of the business's stock in a transaction that occurred on Wednesday, June 11th. The stock was purchased at an average cost of GBX 79 ($1.08) per share, for a total transaction of £149.31 ($203.28).
Dr. Martens Stock Down 0.9%
Dr. Martens stock traded down GBX 0.70 ($0.01) during trading on Friday, reaching GBX 75.80 ($1.03). 1,895,532 shares of the company's stock were exchanged, compared to its average volume of 2,274,796. Dr. Martens plc has a 52-week low of GBX 43.02 ($0.59) and a 52-week high of GBX 85.10 ($1.16). The firm has a market cap of £735.84 million, a price-to-earnings ratio of 10.75, a PEG ratio of 6.40 and a beta of 0.11. The company has a debt-to-equity ratio of 127.27, a quick ratio of 1.13 and a current ratio of 2.85. The company's 50-day moving average is GBX 57.68 and its two-hundred day moving average is GBX 63.41.
Dr. Martens (LON:DOCS - Get Free Report) last issued its earnings results on Thursday, June 5th. The company reported GBX 2.40 ($0.03) earnings per share for the quarter. Dr. Martens had a return on equity of 18.91% and a net margin of 7.89%. On average, analysts predict that Dr. Martens plc will post 2.5809394 earnings per share for the current year.
Dr. Martens Cuts Dividend
The company also recently disclosed a dividend, which was paid on Tuesday, April 8th. Stockholders of record on Thursday, March 6th were paid a dividend of GBX 0.85 ($0.01) per share. The ex-dividend date of this dividend was Thursday, March 6th. This represents a dividend yield of 1.47%. Dr. Martens's dividend payout ratio is currently 42.53%.
Wall Street Analyst Weigh In
Separately, Royal Bank of Canada reduced their price target on shares of Dr. Martens from GBX 7,000 ($95.30) to GBX 6,000 ($81.69) and set a "sector perform" rating on the stock in a research report on Monday, May 19th.
Read Our Latest Stock Report on Dr. Martens
Dr. Martens Company Profile
(
Get Free Report)
Dr. Martens is an iconic British brand founded in 1960 in Northamptonshire. Originally produced for workers looking
for tough, durable boots, the brand was quickly adopted by diverse youth subcultures and associated musical
movements. Dr. Martens have since transcended their working-class roots while still celebrating their proud heritage
and, six decades later, “Docs” or “DMs” are worn by people around the world who use them as a symbol of
empowerment and their own individual attitude.
The Company successfully listed on the main market of the London Stock Exchange on 29 January 2021 (DOCS.L) and
is a constituent of the FTSE 250 index.
Read More
Before you consider Dr. Martens, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dr. Martens wasn't on the list.
While Dr. Martens currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
